Insight journal

Life Science Intelligence for Deal Makers
Welcome to Insight Journal, where you can explore a series of articles and posts written by CP analysts that cover recent partnering trends, significant deals, company partnering strategies and therapy forecasts.

These articles have been written not only to give you insights but advice into popular issues such as the top therapeutic areas and companies to partner with, as well as providing opinion on the latest deal talk.

Insight journal is regularly updated with breaking news as it happens and rumours of potential deals. 

CP Insight: Login | More details | Subscription options

Featured insights

Pharmacyclics: Partnering activity 2009-2014

October 20, 2014 : biopharmaceutical, oncology

Pharmacyclics, listed as a new big biotech entrant in 2014, works to improve the lives of cancer affected patients by entering into strategic partnering deals to support its product pipeline. more »

Nektar Therapeutics – Well respected partner of choice

October 10, 2014 : big biotech, biotech partnering, Nektar Therapeutics, partnering

Nektar therapeutics is a leading biopharma company developing clinical stage products based upon its advanced polymer conjugate chemistry technology. more »

Isis Pharmaceuticals: Partnering activity 2009-2014

September 15, 2014 : cardiovascular, oncology, pharmaceuticals

Isis Pharmaceuticals, a leader in antisense drug discovery, has emerged as a top 50 big biotech company with its business strategy. more »

MorphoSys M&A deals 2009-2014

September 12, 2014 : antibodies, MorphoSys

MorphoSys has announced only one acquisition in the past 5 years. more »

Jazz Pharmaceuticals – A new entry into the top 50 biotech of 2014

September 8, 2014 : biopharmaceutical, leukemia, narcolepsy, oncology

Headquartered in Dublin, Ireland Jazz Pharmaceuticals is a specialty biopharmaceuticals company that has undergone significant growth in recent years. Jazz Pharmaceuticals is focused upon delivering products for cataplexy, narcolepsy, oncology/leukemia, chronic pain and non-opioid schizophrenia.   more »


Company insights

Therapy insights

Technology insights

Deals and alliances insights

Dealtalk Insights

Print Friendly
RSS Feed Linked In Twitter

Latest Tweets